Ezetimibe increases hepatic iron levels in mice fed a high-fat diets

Journal of Pharmacology and Experimental Therapeutics

Volumn 345, Issue 3, 2013, Pages 483-491

  Kishino, Yoshizumi ^a,b   Tanaka, Yuji ^a   Ikeda, Takanori ^c   Yamamoto, Kazuo ^a   Ogawa, Hiroshi ^c   Iwatani, Yoshinori ^b   Kamisako, Toshinori ^a  

^a KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b OSAKA UNIVERSITY   (Japan)

^c Tezukayama Gakuin University   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ACYL COENZYME A OXIDASE; ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; CD71 ANTIGEN; CHOLESTEROL; EZETIMIBE; FAS ANTIGEN; FERRITIN; FERRITIN H; FERRITIN L; HEMOJUVELIN; HEPCIDIN; HEPHAESTIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; IRON; MESSENGER RNA; NATURAL RESISTANCE ASSOCIATED MACROPHAGE PROTEIN 2; NEOGENIN; STEROL REGULATORY ELEMENT BINDING PROTEIN 1C; STEROL REGULATORY ELEMENT BINDING PROTEIN 2; TRANSFERRIN RECEPTOR 2; UNCLASSIFIED DRUG;

3 HYDROXY 3 METHYLGLUTARYL COENZYME A REDUCTASE GENE; ACYL COA OXIDASE GENE; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIVALENT TRANSPORTER 1 GENE; DRUG EFFECT; FAS GENE; FATTY LIVER; FERRITIN H GENE; FERRITIN L GENE; FERROPORTIN 1 GENE; GENE; GENE EXPRESSION; GENE FUNCTION; GENE IDENTIFICATION; HEMOJUVELIN GENE; HEPCIDIN GENE; HEPHAESTIN GENE; IRON BINDING CAPACITY; IRON BLOOD LEVEL; IRON METABOLISM; IRON TRANSPORT; LIPID DIET; LIPID METABOLISM; LIVER WEIGHT; MALE; MOUSE; NEOGENIN GENE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; STEROL REGULATORY ELEMENT BINDING PROTEIN 1C GENE; STEROL REGULATORY ELEMENT BINDING PROTEIN 2 GENE; TRANSFERRIN RECEPTOR 2 GENE;

ANIMALS; ANTICHOLESTEREMIC AGENTS; AZETIDINES; BIOLOGICAL MARKERS; BODY WEIGHT; CHOLESTEROL; DIET, HIGH-FAT; FATTY ACIDS; GENE EXPRESSION; IRON; LIPID METABOLISM; LIVER; MALE; MICE; MICE, INBRED C57BL; ORGAN SIZE; REAL-TIME POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 84878061834     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.113.203448     Document Type: Article

References (53)

1. Ahmed U and Oates PS (2013) Dietary fat level affects tissue iron levels but not the iron regulatory gene HAMP in rats. Nutr Res 33:126-135.
2. Aigner E, Theurl I, Theurl M, Lederer D, Haufe H, Dietze O, Strasser M, Datz C, and Weiss G (2008) Pathways underlying iron accumulation in human nonalcoholic fatty liver disease. Am J Clin Nutr 87:1374-1383.
3. Altmann SW, Davis HR, Jr, Zhu LJ, Yao X, Hoos LM, Tetzloff G, Iyer SP, Maguire M, Golovko A, and Zeng M, et al. (2004) Niemann-Pick C1 Like 1 protein is critical for intestinal cholesterol absorption. Science 303:1201-1204.
4. Berson A, De Beco V, Lettéron P, Robin MA, Moreau C, El Kahwaji J, Verthier N, Feldmann G, Fromenty B, and Pessayre D (1998) Steatohepatitis- inducing drugs cause mitochondrial dysfunction and lipid peroxidation in rat hepatocytes. Gastroenterology 114:764-774.
5. Chung J, Kim MS, and Han SN (2011) Diet-induced obesity leads to decreased hepatic iron storage in mice. Nutr Res 31:915-921.
6. Day CP and James OF (1998) Steatohepatitis: A tale of two "hits"? Gastroenterology 114:842-845.
7. de Bari O, Neuschwander-Tetri BA, Liu M, Portincasa P, and Wang DQ (2012) Ezetimibe: Its novel effects on the prevention and the treatment of cholesterol gallstones and nonalcoholic fatty liver disease. J Lipids 2012:302847 .
8. Dupic F, Fruchon S, Bensaid M, Loreal O, Brissot P, Borot N, Roth MP, and Coppin H (2002) Duodenal mRNA expression of iron related genes in response to iron loading and iron deficiency in four strains of mice. Gut 51:648-653.
9. Fleming RE, Migas MC, Holden CC, Waheed A, Britton RS, Tomatsu S, Bacon BR, and Sly WS (2000) Transferrin receptor 2: Continued expression in mouse liver in the face of iron overload and in hereditary hemochromatosis. Proc Natl Acad Sci USA 97:2214-2219.
10. Folch J, Lees M, and Sloane Stanley GH (1957) A simple method for the isolation and purification of total lipides from animal tissues. J Biol Chem 226:497-509.
11. Forouhi NG, Harding AH, Allison M, Sandhu MS, Welch A, Luben R, Bingham S, Khaw KT, and Wareham NJ (2007) Elevated serum ferritin levels predict newonset type 2 diabetes: Results from the EPIC-Norfolk prospective study. Diabetologia 50:949-956.
12. Garcia-Calvo M, Lisnock J, Bull HG, Hawes BE, Burnett DA, Braun MP, Crona JH, Davis HR, Jr, Dean DC, and Detmers PA, et al. (2005) The target of ezetimibe is Niemann-Pick C1-like 1 (NPC1L1). Proc Natl Acad Sci USA 102:8132-8137.
13. Geier A, Dietrich CG, Grote T, Beuers U, Prüfer T, Fraunberger P, Matern S, Gartung C, Gerbes AL, and Bilzer M (2005) Characterization of organic anion transporter regulation, glutathione metabolism and bile formation in the obese Zucker rat. J Hepatol 43:1021-1030.
14. George DK, Goldwurm S, MacDonald GA, Cowley LL, Walker NI, Ward PJ, Jazwinska EC, and Powell LW (1998) Increased hepatic iron concentration in nonalcoholic steatohepatitis is associated with increased fibrosis. Gastroenterology 114:311-318.
15. Graham RM, Chua AC, Carter KW, Delima RD, Johnstone D, Herbison CE, Firth MJ, O'Leary R, Milward EA, and Olynyk JK, et al. (2010) Hepatic iron loading in mice increases cholesterol biosynthesis. Hepatology 52:462-471.
16. Hardwick RN, Fisher CD, Street SM, Canet MJ, and Cherrington NJ (2012) Molecular mechanism of altered ezetimibe disposition in nonalcoholic steatohepatitis. Drug Metab Dispos 40:450-460.
17. Herbison CE, Thorstensen K, Chua AC, Graham RM, Leedman P, Olynyk JK, and Trinder D (2009) The role of transferrin receptor 1 and 2 in transferrin-bound iron uptake in human hepatoma cells. Am J Physiol Cell Physiol 297: C1567-C1575.
18. Iqbal J and Hussain MM (2009) Intestinal lipid absorption. Am J Physiol Endocrinol Metab 296:E1183-E1194.
19. Jiang R, Manson JE, Meigs JB, Ma J, Rifai N, and Hu FB (2004) Body iron stores in relation to risk of type 2 diabetes in apparently healthy women. JAMA 291: 711-717.
20. Jehn M, Clark JM, and Guallar E (2004) Serum ferritin and risk of the metabolic syndrome in U.S. adults. Diabetes Care 27:2422-2428.
21. Kiessling MK, Klemke CD, Kaminski MM, Galani IE, Krammer PH, and Gülow K (2009) Inhibition of constitutively activated nuclear factor-kB induces reactive oxygen species-and iron-dependent cell death in cutaneous T-cell lymphoma. Cancer Res 69:2365-2374.
22. Kirsch R, Sijtsema HP, Tlali M, Marais AD, and Hall PdeL (2006) Effects of iron overload in a rat nutritional model of non-alcoholic fatty liver disease. Liver Int 26: 1258-1267.
23. Koek GH, Liedorp PR, and Bast A (2011) The role of oxidative stress in non-alcoholic steatohepatitis. Clin Chim Acta 412:1297-1305.
24. Kolouchova G, Brcakova E, Hirsova P, Cermanova J, Fuksa L, Mokry J, Nachtigal P, Lastuvkova H, and Micuda S (2011) Modification of hepatic iron metabolism induced by pravastatin during obstructive cholestasis in rats. Life Sci 89: 717-724.
25. Krawczyk M, Bonfrate L, and Portincasa P (2010) Nonalcoholic fatty liver disease. Best Pract Res Clin Gastroenterol 24:695-708.
26. Lickteig AJ, Fisher CD, Augustine LM, Aleksunes LM, Besselsen DG, Slitt AL, Manautou JE, and Cherrington NJ (2007) Efflux transporter expression and acetaminophen metabolite excretion are altered in rodent models of nonalcoholic fatty liver disease. Drug Metab Dispos 35:1970-1978.
27. Lin X, Chen Z, Yue P, Averna MR, Ostlund RE, Jr, Watson MA, and Schonfeld G (2006) A targeted apoB38.9 mutation in mice is associated with reduced hepatic cholesterol synthesis and enhanced lipid peroxidation. Am J Physiol Gastrointest Liver Physiol 290:G1170-G1176.
28. Muraoka T, Aoki K, Iwasaki T, Shinoda K, Nakamura A, Aburatani H, Mori S, Tokuyama K, Kubota N, and Kadowaki T, et al. (2011) Ezetimibe decreases SREBP-1c expression in liver and reverses hepatic insulin resistance in mice fed a high-fat diet. Metabolism 60:617-628.
29. Nelson JE, Klintworth H, and Kowdley KV (2012) Iron metabolism in nonalcoholic fatty liver disease. Curr Gastroenterol Rep 14:8-16.
30. Nelson JE, Wilson L, Brunt EM, Yeh MM, Kleiner DE, Unalp-Arida A, and Kowdley KV; Nonalcoholic Steatohepatitis Clinical Research Network (2011) Relationship between the pattern of hepatic iron deposition and histological severity in nonalcoholic fatty liver disease. Hepatology 53:448-457.
31. Oswald S, May K, Rosin J, Lütjohann D, and Siegmund W (2010) Synergistic influence of Abcb1 and Abcc2 on disposition and sterol lowering effects of ezetimibe in rats. J Pharm Sci 99:422-429.
32. Oswald S, Westrup S, Grube M, Kroemer HK, Weitschies W, and SiegmundW (2006) Disposition and sterol-lowering effect of ezetimibe in multidrug resistanceassociated protein 2-deficient rats. J Pharmacol Exp Ther 318:1293-1299.
33. Papanikolaou G and Pantopoulos K (2005) Iron metabolism and toxicity. Toxicol Appl Pharmacol 202:199-211.
34. Park H, Shima T, Yamaguchi K, Mitsuyoshi H, Minami M, Yasui K, Itoh Y, Yoshikawa T, Fukui M, and Hasegawa G, et al. (2011) Efficacy of long-term ezetimibe therapy in patients with nonalcoholic fatty liver disease. J Gastroenterol 46: 101-107.
35. Paraskevas KI, Pantopoulou A, Vlachos IS, Agrogiannis G, Iliopoulos DG, Karatzas G, Tzivras D, Mikhailidis DP, and Perrea DN (2011) Comparison of fibrate, ezetimibe, low-and high-dose statin therapy for the dyslipidemia of the metabolic syndrome in a mouse model. Angiology 62:144-154.
36. Ramey G, Deschemin JC, Durel B, Canonne-Hergaux F, Nicolas G, and Vaulont S (2010) Hepcidin targets ferroportin for degradation in hepatocytes. Haematologica 95:501-504.
37. Smith BW and Adams LA (2011) Non-alcoholic fatty liver disease. Crit Rev Clin Lab Sci 48:97-113.
38. Sumida Y, Yoshikawa T, and Okanoue T (2009) Role of hepatic iron in non-alcoholic steatohepatitis. Hepatol Res 39:213-222.
39. Tamaki N, Ueno H, Morinaga Y, Shiiya T, and Nakazato M (2012) Ezetimibe ameliorates atherosclerotic and inflammatory markers, atherogenic lipid profiles, insulin sensitivity, and liver dysfunction in Japanese patients with hypercholesterolemia. J Atheroscler Thromb 19:532-538.
40. Tanaka Y, Ikeda T, Yamamoto K, Ogawa H, and Kamisako T (2012) Dysregulated expression of fatty acid oxidation enzymes and iron-regulatory genes in livers of Nrf2-null mice. J Gastroenterol Hepatol 27:1711-1717.
41. Theurl I, Ludwiczek S, Eller P, Seifert M, Artner E, Brunner P, and Weiss G (2005) Pathways for the regulation of body iron homeostasis in response to experimental iron overload. J Hepatol 43:711-719.
42. Tomkin GH (2008) The intestine as a regulator of cholesterol homeostasis in diabetes. Atheroscler Suppl 9:27-32.
43. Torrance JD and Bothwell TH (1980) Tissue iron stores, in Iron (Cook JD, ed, ed) pp 90-115, Livingstone, New York.
44. Tsuchiya H, Ashla AA, Hoshikawa Y, Matsumi Y, Kanki K, Enjoji M, Momosaki S, NakamutaM, Taketomi A, andMaehara Y, et al. (2010a) Iron state in association with retinoid metabolism in non-alcoholic fatty liver disease. Hepatol Res 40:1227-1238.
45. Tsuchiya H, Sakabe T, Akechi Y, Ikeda R, Nishio R, Terabayashi K, Matsumi Y, Hoshikawa Y, Kurimasa A, and Shiota G (2010b) A close association of abnormal iron metabolism with steatosis in the mice fed a choline-deficient diet. Biol Pharm Bull 33:1101-1104.
46. Vokurka M, Krijt J, Sulc K, and Necas E (2006) Hepcidin mRNA levels in mouse liver respond to inhibition of erythropoiesis. Physiol Res 55:667-674.
47. Wallace DF, Summerville L, Lusby PE, and Subramaniam VN (2005) First phenotypic description of transferrin receptor 2 knockout mouse, and the role of hepcidin. Gut 54:980-986.
48. Wang W, Reeves WB, and Ramesh G (2009) Netrin-1 increases proliferation and migration of renal proximal tubular epithelial cells via the UNC5B receptor. Am J Physiol Renal Physiol 296:F723-F729.
49. Weinberg ED (2010) The hazards of iron loading. Metallomics 2:732-740.
50. Yoneda M, Fujita K, Imajo K,Mawatari H, Kirikoshi H, Saito S, and Nakajima A (2011) Induction of microsomal triglyceride transfer protein expression is a candidate mechanism by which ezetimibe therapy might exert beneficial effects in patients with nonalcoholic steatohepatitis. J Gastroenterol 46:415-416, author reply 417.
51. Yunoki K, Nakamura K, Miyoshi T, Enko K, Kohno K, Morita H, Kusano KF, and Ito H (2011) Ezetimibe improves postprandial hyperlipemia and its induced endothelial dysfunction. Atherosclerosis 217:486-491.
52. Zhang AS, Yang F, Wang J, Tsukamoto H, and Enns CA (2009) Hemojuvelinneogenin interaction is required for bone morphogenic protein-4-induced hepcidin expression. J Biol Chem 284:22580-22589.
53. Zheng S, Hoos L, Cook J, Tetzloff G, Davis H, Jr, van Heek M, and Hwa JJ (2008) Ezetimibe improves high fat and cholesterol diet-induced non-alcoholic fatty liver disease in mice. Eur J Pharmacol 584:118-124.